durvalumab

Overview

Durvalumab is a human monoclonal antibody that targets CD274 molecule (PD-L1), a protein that plays a crucial role in the immune system's ability to recognize and attack cancer cells. By inhibiting the interaction between PD-L1 and its receptor, programmed cell death protein 1 (PD-1), durvalumab enhances T-cell activation and proliferation, thereby promoting an anti-tumor immune response. This mechanism positions durvalumab as a significant player in cancer immunotherapy, particularly in the treatment of various malignancies, including non-small cell lung cancer (NSCLC), bladder cancer, and hepatocellular carcinoma (HCC).

Recent Publications Summary

Recent clinical studies have evaluated durvalumab across multiple cancer types, with particular emphasis on combination regimens and patient stratification by biomarkers. In lung Cancers, durvalumab has been investigated in extensive-stage small-cell lung cancer (ES-SCLC) combined with olaparib as maintenance therapy following platinum-etoposide induction, with multi-omics analyses identifying molecular subtypes associated with clinical benefit 42601174Aug. Similar combination approaches have been explored in large-cell neuroendocrine lung carcinoma, where durvalumab plus platinum-etoposide was evaluated as first-line treatment 42526918Jul, and in EGFR-mutated advanced NSCLC with neuroendocrine transformation, where durvalumab plus etoposide-platinum demonstrated a 43% confirmed objective response rate 42361644Jun. For limited-stage SCLC, durvalumab was studied concurrently with chemoradiotherapy 41832629Mar, while in oligometastatic NSCLC, durvalumab was combined with chemotherapy and stereotactic ablative radiotherapy 41005623Sep.

In hepatocellular carcinoma, durvalumab has emerged as a key component of dual immune checkpoint blockade strategies. The STRIDE regimen combining durvalumab with tremelimumab has been compared head-to-head with atezolizumab plus bevacizumab, with baseline des-γ-carboxy prothrombin (DCP) levels potentially modifying treatment response 42477505Jul. Pretreatment intratumoral CD8+ T cell density was associated with response to tremelimumab plus durvalumab 42373240Jun, and real-world data confirmed the tolerability and safety profile of STRIDE in routine practice 41992826Apr. An intensified approach combining hepatic arterial infusion chemotherapy with FOLFOX, lenvatinib, and durvalumab demonstrated a median progression-free survival of 15.8 months and 2-year overall survival of 94.0% in unresectable HCC 42135293May. The albumin-bilirubin score was identified as a prognostic biomarker for outcomes in advanced biliary tract cancer treated with durvalumab plus gemcitabine-cisplatin 42095607May.

Durvalumab has shown significant activity in muscle-invasive bladder cancer through perioperative approaches. The NIAGARA trial demonstrated that perioperative durvalumab plus gemcitabine and cisplatin improved event-free survival compared to chemotherapy alone, with mixture cure modeling suggesting an increased cure fraction (60% vs. 41% in control) 42247881Jun42053502Apr. FDA approval for this indication was granted on March 28, 2025, based on NIAGARA's demonstrated improvements in event-free survival and pathologic complete response 41678313Feb. Neoadjuvant combination with dose-dense MVAC and tremelimumab (NEMIO trial) achieved a 48.70% pathologic complete response rate 42190158May.

Durvalumab has been evaluated in breast and gynecologic malignancies with varying biomarker strategies. In triple-negative breast cancer, the BEGONIA platform trial assessed durvalumab plus paclitaxel combined with the pan-AKT inhibitor capivasertib or the anti-CD73 antibody oleclumab, with grade 3/4 adverse event rates ranging from 24.2% to 80.6% depending on the combination 42189888May. Long-term follow-up from the GeparNuevo trial in early triple-negative breast cancer showed sustained improvements in invasive disease-free survival, distant disease-free survival, and overall survival with neoadjuvant durvalumab plus chemotherapy 42008768Apr. In advanced endometrial cancer, the DUO-E trial evaluated durvalumab with or without olaparib following chemotherapy, with exploratory biomarker analyses in the mismatch repair proficient subpopulation 41943281Apr41690202Feb, and in metastatic castration-resistant prostate cancer, olaparib combined with durvalumab resulted in a median radiographic progression-free survival of 5.0 months 41881502Mar.

Mechanistic studies have begun to clarify resistance pathways and combination strategies. In gallbladder cancer, the ERR𝛼-ETV5-PD-L1 signaling axis was identified as a driver of immune escape, and combined targeting of ERR𝛼 with durvalumab synergistically suppressed tumor growth and enhanced CD8+ T cell infiltration in models 41791643Mar. A phase 1 trial of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab was conducted in recurrent/metastatic NSCLC and head and neck squamous cell carcinoma 41917211Mar, while the MONETTE trial evaluated ceralasertib plus durvalumab in PD-(L)1 resistant melanoma, though the combination did not meet the prespecified efficacy threshold 42012456Apr.

What Changes, What Holds

1. Small-cell lung cancer achieves durable responses with durvalumab-based combinations stratified by molecular subtype
REINFORCES ES-SCLC and limited-stage SCLC responded to durvalumab combined with olaparib maintenance and concurrent chemoradiotherapy respectively 42601174Aug41832629Mar. EGFR-mutated NSCLC with neuroendocrine transformation and large-cell neuroendocrine carcinoma similarly showed benefit, with multi-omics analyses identifying molecular subtypes predicting clinical advantage. This extends the baseline's NSCLC indication to histologically distinct small-cell tumors and neuroendocrine variants using the same PD-L1 blockade mechanism, though prospective biomarker validation of molecular stratification requires further study.

2. dual immune checkpoint blockade emerges as superior strategy to monotherapy in hepatocellular carcinoma
NEW DIRECTION Durvalumab combined with tremelimumab (CTLA-4 inhibitor) improved outcomes compared to atezolizumab-bevacizumab in HCC, with biomarker-directed selection using DCP levels and intratumoral CD8+ density, while intensified multimodal therapy integrating hepatic arterial infusion chemotherapy with FOLFOX, lenvatinib, and durvalumab achieved 94% two-year overall survival in unresectable disease 42477505Jul42135293May. The baseline does not address dual checkpoint inhibition or this intensified approach, establishing a new strategic direction for HCC treatment.

3. Perioperative durvalumab-based chemotherapy improves cure fraction in muscle-invasive bladder cancer with FDA approval
REINFORCES NIAGARA demonstrated that perioperative durvalumab plus gemcitabine-cisplatin improved event-free survival with mixture cure modeling suggesting 60% versus 41% control cure fraction, securing FDA approval March 28, 2025 42247881Jun41678313Feb. This extends the baseline's bladder cancer indication from advanced disease into curative-intent perioperative settings, demonstrating durvalumab's potential to drive durable remission when combined with chemotherapy in muscle-invasive disease.

4. Durvalumab demonstrates activity across triple-negative breast cancer, endometrial cancer, and prostate cancer
REINFORCES Durvalumab plus paclitaxel with capivasertib or oleclumab showed activity in triple-negative breast cancer, while neoadjuvant durvalumab-chemotherapy improved survival in early disease 42189888May42008768Apr. Similar combinations were explored in advanced endometrial cancer and metastatic castration-resistant prostate cancer. These findings extend the baseline's scope to histologically distinct malignancies using durvalumab's established PD-L1 blockade mechanism, though efficacy and safety profiles remain incompletely characterized.

5. Immune escape via ERR𝛼-ETV5-PD-L1 signaling may drive resistance, though combination rescue strategies show limited efficacy
NEW DIRECTION Gallbladder cancer cells employ ERR𝛼-ETV5-PD-L1 signaling to evade immunity, with preclinical work suggesting combined ERR𝛼 targeting enhances durvalumab efficacy, yet MONETTE's ceralasertib-durvalumab combination failed to overcome PD-(L)1 resistance in melanoma 41791643Mar42012456Apr. The baseline provides no account of resistance mechanisms or therapeutic escape, establishing that some immuno-evasive pathways may resist combination-based rescue despite mechanistic rationale.

Overview update candidates: Small-cell lung cancer indications with molecular stratification; dual checkpoint blockade strategy in hepatocellular carcinoma; perioperative durvalumab in muscle-invasive bladder cancer (FDA approval March 2025); and extension to breast and gynecologic malignancies.